Uncover Two Stellar Investment Opportunities Worth Pursuing with a $1,000 Budget Immediately
Investing in reliable businesses that foster long-term portfolio growth is always advantageous. It's crucial to apply a discerning eye when choosing companies for your portfolio and invest only in ventures that align with your investment philosophy, risk tolerance, and long-term ambitions. The funds you deploy should ideally remain untouched for several years, avoiding those required for immediate expenses or obligations.
If you're in search of top-notch growth stocks at present and have $1,000 to spare, consider these two contenders.
1. Eli Lilly
Eli Lilly, ticker symbol LLY (-0.44%), has graced the pharmaceutical sector for the past 12 to 18 months, with shares soaring as a result of its GLP-1 drugs' popularity, which subsequently boosted revenue and earnings. Keep in mind that this enterprise boasts an extensive history in healthcare, with its arsenal of best-selling drugs covering various tumors, cardiovascular ailments, endocrine disorders, and neurological conditions.
During the first nine months of 2025, shares shot up around 62%. In response to the company's third-quarter earnings report for 2025, shares took a double-digit plunge when investors reacted negatively to a few aspects, such as a slight moderation in full-year guidance and earnings figures that fell slightly below Wall Street's expectations. The company now predicts annual revenue in the $45.4 billion to $46 billion range, down from its initial projection of $45.4 billion to $46.6 billion.
That said, it's worth exploring further, as the outlook for this business is anything but grim. Eli Lilly's Q3 2025 revenue admittedly missed analyst projections, but it still rose 20% year over year to $11.4 billion. The sale of its olanzapine portfolio in Q3, which consists of treatments for disorders like schizophrenia and bipolar disorder, also affected the numbers. However, if you exclude revenue generated by this portfolio, Eli Lilly's income surged 42% year over year.
Tirzepatide is the primary active ingredient in Eli Lilly's top-sellers Mounjaro (for diabetes) and Zepbound (for weight loss). This substance is currently being researched by Eli Lilly across several other disease categories, including its positive phase 3 trial results in a 176-week study that demonstrated a 94% reduction in type 2 diabetes risk in obese or overweight adults with pre-diabetes.
Another groundbreaking study led by Eli Lilly is examining tirzepatide's efficacy in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. In this phase 3 trial, tirzepatide decreased heart failure symptoms, physical limitations, and lowered the risk of heart failure events by 38%. The risk of hospitalization for heart failure was also reduced by 56% for trial participants using tirzepatide. The revenue and profit potential opportunities from tirzepatide may still be in their infancy.
In Q3, sales of Mounjaro rose more than 121% year over year to $3.1 billion, while Zepbound (recently authorized last November) raked in $1.3 billion in sales. These figures were reduced due to negative effects caused by inventory decreases in the wholesaler channel for both drugs. Verzenio, a blockbuster cancer treatment, generated $1.37 billion in sales in the quarter, a 32% increase over the previous year, while Taltz sales soared 18% to $879.6 million.
Investors appear to be highly reactive in the current climate, which may provide opportunities for those with a long-term investment horizon to secure a piece of the action. Although Eli Lilly doesn't carry an appealing valuation, its $5.20 annual dividend and consistent increase in payouts can contribute to overall investor rewards. Potential investors looking to become part-owners in a renowned healthcare company with a broad global presence might overlook this excellent stock if they don't carefully consider it.
2. Monday.com
Monday.com, ticker symbol MNDY (0.58%), is a low-code and no-code platform that empowers organizations to develop and customize the work management tools and software applications required for smooth business operations. Monday.com generates revenue through monthly or annual subscription agreements with customers who utilize its cloud-based platform.
Monday.com's software enables project management, collaboration, and centralized file storage. Clients with little to no coding experience can incorporate its platform to create customized workflow apps, which integrate boards, charts, and other automation solutions.
Businesses such as Canva, Lionsgate, and Coca-Cola are just a few of the notable names on Monday.com's client roster. Investors have recently displayed enthusiasm for Monday.com's performance, with shares surging around 50% over the previous 12 months.
Always, the stock price shouldn't dictate your buying or selling decision. You should delve into the enterprise's fundamentals, its growth drivers and obstacles, financial health, sector, and future growth trajectory to get a thorough understanding of whether it's a suitable investment. For instance, Monday.com, a relatively new entrant in the market since 2012, is still in its growth phase.
Managers anticipate the company to operate in a substantial and growing total addressable market, potentially reaching a valuation of $150 billion by 2026. The broad array of offerings on Monday.com's platform enables it to tap into various segments of its overall market potential, such as the $30 billion customer relationship management (CRM) software market.
From a financial standpoint, Monday.com is performing admirably. Its Q3 revenue soared by 33% year-over-year to $251 million, surpassing the $1 billion annual recurring revenue (ARR) milestone. Furthermore, its overall net dollar retention rate (NRR) climbed to 111%, while NRR for clients with over $100,000 in ARR was 115%.
The proportion of paid customers with over $100,000 in ARR increased by 44% compared to last year. Additionally, Monday.com's second-largest client, an unidentified international technology company, significantly expanded its user base to 60,000 seats from 25,000. Although Monday.com does not meet the profitability criteria under generally accepted accounting principles (GAAP), cash flow is an essential profitability indicator to take into account.
From a free cash flow perspective, the company amassed $82.4 million in free cash flow, and net cash provided by operating activities was $86.6 million in Q3. Despite the inherent risk involved in investing in software stocks, this robust business could be an appealing addition to a diversified portfolio.
- Given the advantageous nature of investing in reliable businesses, allocating some of your finance towards Eli Lilly's stock could be a wise decision due to its promising growth in the pharmaceutical sector and potential revenue opportunities from its innovative drugs like Tirzepatide.
- If you're looking for an opportunity to invest in a growing sector, Monday.com, a low-code platform, might be a worthwhile consideration. With significant growth in its market potential and impressive financial performance, it could contribute positively to a diversified investment portfolio.
